Antibody Drug Conjugates: A Leap Ahead in Cancer Treatment

  • Harsharan Pal Singh Amity Institute of Pharmacy
  • Sumeet Gullaiya Amity Institute of Pharmacy
  • Ishpreet Kaur Delhi Institute of Pharmaceutical Sciences and Research

Abstract

Monoclonal antibody (MAb) based targeted therapies have achieved appreciable success in various branches of drug therapeutics, predominantly when used along with cytotoxic drugs. These immunological therapies based on antibody-drug conjugates (ADCs) have been recently encouraged by the US Food and Drug Administration to treat Solid tumours, Melanoma, Breast Cancer and Hodgkin’s lymphoma. Antibody drug conjugates (ADCs) are an important division of therapeutics that allows the antigen-selective ability of MAbs to deliver highly potent cytotoxic drugs at the site of antigen-expressing tumor cells. The use of MAb directed delivery can confer a high therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. In other words, to achieve the goal of highly improved therapeutic efficacy and reduced toxicity, each component of an ADC i.e. the MAb, linker and the drug needs to be considered in context of targeted antigen. Furthermore, the mechanism of ADCs, characteristics of targets, methods of preparation, linker drugs being used in ADC design and regulatory requirements for new drug approval are discussed.

Downloads

Download data is not yet available.

Author Biographies

Harsharan Pal Singh, Amity Institute of Pharmacy

Amity Institute of Pharmacy, Amity University,Noida

Student

Sumeet Gullaiya, Amity Institute of Pharmacy
Department of Pharmacology,Amity Institute of Pharmacy
Ishpreet Kaur, Delhi Institute of Pharmaceutical Sciences and Research
Delhi Institute of Pharmaceutical Sciences and Research
Statistics
212 Views | 250 Downloads
How to Cite
1.
Singh H, Gullaiya S, Kaur I. Antibody Drug Conjugates: A Leap Ahead in Cancer Treatment. JDDT [Internet]. 15May2014 [cited 4Dec.2021];4(3):52-9. Available from: https://jddtonline.info/index.php/jddt/article/view/832